BlackRock
PBLA

BlackRock’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

BlackRock’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1
Closed -$61K – 6078
2022
Q1 		$61K Hold
1
– – ﹤0.01% 5388
2021
Q4 		$52K Hold
1
– – ﹤0.01% 5394
2021
Q3 		$64K Hold
1
– – ﹤0.01% 5246
2021
Q2 		$68K Buy
+1
New +$97.5K ﹤0.01% 5139

Other funds holding PBLA

BAMG
Brand Asset Management Group Chesterfield, Missouri $385M AUM 22.41% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

BlackRock's PBLA Position: Q2 2022 in Review

BlackRock sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q2 2022, closing a stake of 1 share — an estimated $61K sold.

BlackRock first reported a position in PBLA in Q2 2021 and held it in 4 quarters. The position peaked at $68K in Q2 2021. 7 funds tracked by Wall St. Rank hold PBLA as of Q2 2022.

  • BlackRock reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • BlackRock sold 1 Panbela Therapeutics, Inc. Common Stock share in Q2 2022, an estimated $61K.
  • BlackRock first reported a position in Panbela Therapeutics, Inc. Common Stock in Q2 2021 and held it in 4 quarters.
  • BlackRock's Panbela Therapeutics, Inc. Common Stock position peaked at $68K in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.